Highlights

• FY26 full-year results released on 25 August 2026

• Jason Martinez appointed as Managing Director and CEO in August

• New CFO also announced around the results period

• Company focused on improving operational and financial performance across ANZ

Integral Diagnostics (ASX: IDX) is one of Australia's largest listed radiology providers, operating diagnostic imaging clinics — MRI, CT, X-ray, ultrasound — across Australia and New Zealand. The radiology sector is structurally supported by ageing population demographics, growing chronic disease prevalence and an increasing reliance on imaging for medical decision-making. IDX competes with other radiology chains and smaller independent operators, and has been working through a period of Margin pressure driven by staffing costs and the post-pandemic restructuring of the healthcare services industry. The appointment of new Leadership signals the board is taking an active approach to resetting the company's performance trajectory.

Recent Developments

Integral Diagnostics released FY26 full-year results on 25 August, following the appointment of Jason Martinez as Managing Director and CEO earlier in August. The company also announced its new CFO around the results period. The recent reporting cycle therefore combines financial performance with a significant leadership transition as IDX works to improve its operational and financial performance across Australia and New Zealand.

Key Catalysts to Watch

The new management team — particularly CEO Jason Martinez — will be central to IDX's near-term trajectory. Any strategic reset, cost efficiency programme or network rationalisation announced by incoming leadership would be a significant catalyst. Growth in the Volume of imaging referrals, supported by Medicare rebates and healthcare system demand, provides a structural tailwind. Successful integration of any further acquisitions, or the successful recruitment and retention of radiologists to improve capacity utilisation, would also drive financial improvement.

Risks

IDX faces ongoing radiologist and sonographer workforce shortages, which limit capacity and push up labour costs. Medicare rebate indexation has not always kept pace with cost Inflation in the sector. Competition from other radiology groups is significant, and IDX must maintain its referral network relationships. The leadership transition itself is a near-term risk — new CEOs take time to assess the business, make strategic decisions and implement changes, which can create uncertainty.

Conclusion

Integral Diagnostics is at a pivotal moment — new CEO, new CFO, FY26 results all landing at the same time creates both uncertainty and opportunity. The structural Demand for diagnostic imaging is not in question; what investors need to see is evidence that the new leadership team can translate that demand into improved margins and returns. The months ahead, as Jason Martinez begins to articulate his strategy, will be closely watched.